Menu
GWAS Study

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R et al.

25849990 PubMed ID
GWAS Study Type
15222 Participants
4 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

TW
Tapper W
JA
Jones AV
KR
Kralovics R
HA
Harutyunyan AS
ZK
Zoi K
LW
Leung W
GA
Godfrey AL
GP
Guglielmelli P
CA
Callaway A
WD
Ward D
AP
Aranaz P
WH
White HE
WK
Waghorn K
LF
Lin F
CA
Chase A
BE
Baxter EJ
MC
Maclean C
NJ
Nangalia J
CE
Chen E
EP
Evans P
SM
Short M
JA
Jack A
WL
Wallis L
OD
Oscier D
DA
Duncombe AS
SA
Schuh A
MA
Mead AJ
GM
Griffiths M
EJ
Ewing J
GR
Gale RE
SS
Schnittger S
HT
Haferlach T
SF
Stegelmann F
DK
Döhner K
GH
Grallert H
SK
Strauch K
TT
Tanaka T
BS
Bandinelli S
GA
Giannopoulos A
PL
Pieri L
MC
Mannarelli C
GH
Gisslinger H
BG
Barosi G
CM
Cazzola M
RA
Reiter A
HC
Harrison C
CP
Campbell P
GA
Green AR
VA
Vannucchi A
CN
Cross NC
Chapter II

Abstract

Summary of the research findings

Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,083 controls, we identify two SNPs with genome-wide significance in JAK2(V617F)-negative MPN: rs12339666 (JAK2; meta-analysis P=1.27 × 10(-10)) and rs2201862 (MECOM; meta-analysis P=1.96 × 10(-9)). Two additional SNPs, rs2736100 (TERT) and rs9376092 (HBS1L/MYB), achieve genome-wide significance when including JAK2(V617F)-positive cases. rs9376092 has a stronger effect in JAK2(V617F)-negative cases with CALR and/or MPL mutations (Breslow-Day P=4.5 × 10(-7)), whereas in JAK2(V617F)-positive cases rs9376092 associates with essential thrombocythemia (ET) rather than polycythemia vera (allelic χ(2) P=7.3 × 10(-7)). Reduced MYB expression, previously linked to development of an ET-like disease in model systems, associates with rs9376092 in normal myeloid cells. These findings demonstrate that multiple germline variants predispose to MPN and link constitutional differences in MYB expression to disease phenotype.

524 European ancestry JAK2 negative cases, 2,674 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

15222
Total Participants
GWAS
Study Type
Yes
Replicated
1,383 European ancestry JAK2 negative cases, 4,609 European ancestry controls, 526 JAK2 negative cases, 5,506 controls
Replication Participants
European
Ancestry
U.K., Italy, Greece, Germany, Austria
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.